JAMA,
Journal Year:
2020,
Volume and Issue:
unknown
Published: April 13, 2020
Importance
The
pandemic
of
coronavirus
disease
2019
(COVID-19)
caused
by
the
novel
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
presents
an
unprecedented
challenge
to
identify
effective
drugs
for
prevention
and
treatment.
Given
rapid
pace
scientific
discovery
clinical
data
generated
large
number
people
rapidly
infected
SARS-CoV-2,
clinicians
need
accurate
evidence
regarding
medical
treatments
this
infection.
Observations
No
proven
therapies
virus
currently
exist.
expanding
knowledge
SARS-CoV-2
virology
provides
a
significant
potential
drug
targets.
most
promising
therapy
is
remdesivir.
Remdesivir
has
potent
in
vitro
activity
against
but
it
not
US
Food
Drug
Administration
approved
being
tested
ongoing
randomized
trials.
Oseltamivir
been
shown
have
efficacy,
corticosteroids
are
recommended.
Current
does
support
stopping
angiotensin-converting
enzyme
inhibitors
or
angiotensin
receptor
blockers
patients
with
COVID-19.
Conclusions
Relevance
COVID-19
represents
greatest
global
public
health
crisis
generation
and,
potentially,
since
influenza
outbreak
1918.
speed
volume
trials
launched
investigate
highlight
both
capability
produce
high-quality
even
middle
pandemic.
date.
International Journal of Molecular Sciences,
Journal Year:
2020,
Volume and Issue:
21(7), P. 2657 - 2657
Published: April 10, 2020
The
sudden
outbreak
of
2019
novel
coronavirus
(2019-nCoV,
later
named
SARS-CoV-2)
in
Wuhan,
China,
which
rapidly
grew
into
a
global
pandemic,
marked
the
third
introduction
virulent
human
society,
affecting
not
only
healthcare
system,
but
also
economy.
Although
our
understanding
coronaviruses
has
undergone
huge
leap
after
two
precedents,
effective
approaches
to
treatment
and
epidemiological
control
are
still
lacking.
In
this
article,
we
present
succinct
overview
epidemiology,
clinical
features,
molecular
characteristics
SARS-CoV-2.
We
summarize
current
data
from
initial
Wuhan
studies,
emphasize
several
features
SARS-CoV-2,
differentiate
it
SARS-CoV
Middle
East
respiratory
syndrome
(MERS-CoV),
such
as
high
variability
disease
presentation.
systematize
trials
that
have
been
initiated
COVID-19
pandemic.
Whereas
on
SARS-CoV-2
genome-based
specific
vaccines
therapeutic
antibodies
currently
being
tested,
solution
is
more
long-term,
they
require
thorough
testing
their
safety.
On
other
hand,
repurposing
existing
agents
previously
designed
for
virus
infections
pathologies
happens
be
practical
approach
rapid
response
measure
emergent
most
these
already
tested
These
can
divided
broad
categories,
those
directly
target
replication
cycle,
based
immunotherapy
either
aimed
boost
innate
antiviral
immune
responses
or
alleviate
damage
induced
by
dysregulated
inflammatory
responses.
studies
revealed
promising
potential
drugs,
including
Viruses,
Journal Year:
2021,
Volume and Issue:
13(2), P. 202 - 202
Published: Jan. 29, 2021
Three
major
outbreaks
of
the
coronavirus,
a
zoonotic
virus
known
to
cause
respiratory
disease,
have
been
reported
since
2002,
including
SARS-CoV,
MERS-CoV
and
most
recent
2019-nCoV,
or
more
recently
as
SARS-CoV-2.
Bats
are
be
primary
animal
reservoir
for
coronaviruses.
However,
in
past
few
decades,
has
able
mutate
adapt
infect
humans,
resulting
an
animal-to-human
species
barrier
jump.
The
emergence
novel
coronavirus
poses
serious
global
public
health
threat
possibly
carries
potential
causing
pandemic
outbreak
naïve
human
population.
COVID-19,
disease
caused
by
SARS-CoV-2,
Wuhan,
Hubei
Province,
China
infected
over
36.5
million
individuals
claimed
one
lives
worldwide,
8
October
2020.
is
rapidly
spreading
across
transmitted
213
other
countries/territories
globe.
Researchers
that
constantly
evolving
through
asymptomatic
carriers,
further
suggesting
high
threat.
To
this
end,
current
up-to-date
information
on
evolution
SARS-CoV-2
modes
transmission,
detection
techniques
control
prevention
strategies
summarized
review.
Nutrients,
Journal Year:
2020,
Volume and Issue:
12(5), P. 1466 - 1466
Published: May 19, 2020
The
novel
coronavirus
disease
(COVID-19)
pandemic
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
has
engulfed
the
world,
affecting
more
than
180
countries.
As
a
result,
there
been
considerable
economic
distress
globally
and
significant
loss
of
life.
Sadly,
vulnerable
immunocompromised
in
our
societies
seem
to
be
susceptible
COVID-19
complications.
Global
public
health
bodies
governments
have
ignited
strategies
issued
advisories
on
various
handwashing
hygiene
guidelines,
social
distancing
strategies,
and,
most
extreme
cases,
some
countries
adopted
“stay
place”
or
lockdown
protocols
prevent
spread.
Notably,
are
several
risk
factors
for
infection.
These
include
presence
poor
nutritional
status
pre-existing
noncommunicable
diseases
(NCDs)
such
as
diabetes
mellitus,
chronic
lung
diseases,
cardiovascular
(CVD),
obesity,
other
that
render
patient
immunocompromised.
characterized
systemic
inflammation,
which
may
common
feature
these
NCDs,
outcomes
against
COVID-19.
In
this
review,
we
discuss
anti-inflammatory
therapies
currently
under
investigation
intended
dampen
cytokine
storm
infections.
Furthermore,
role
diet
lifestyle
is
considered,
it
known
affect
infections
play
This
review
speculates
importance
nutrition
mitigation
strategy
support
immune
function
amid
pandemic,
identifying
food
groups
key
nutrients
The Indian Journal of Medical Research,
Journal Year:
2020,
Volume and Issue:
151(5), P. 401 - 401
Published: Jan. 1, 2020
The
novel
coronavirus
disease
2019
(COVID-19)
with
its
early
origin
from
Wuhan
city
in
China
has
evolved
into
a
global
pandemic.
Maximal
precautionary
measures
and
resources
have
been
put
forward
by
most
nations
war
footing
to
mitigate
transmission
decrease
fatality
rates.
This
article
was
aimed
review
the
evidence
on
clinical
management
deal
identification
of
high-risk
groups,
warning
signs,
appropriate
investigations,
proper
sample
collection
for
confirmation,
general
specific
treatment
measures,
strategies
as
well
infection
control
healthcare
settings.
Advanced
age,
cardiovascular
disease,
diabetes,
hypertension
cancer
found
be
risk
factors
severe
disease.
Fever
lasting
>five
days
tachypnoea,
tachycardia
or
hypotension
are
indications
urgent
attention
hospitalization
patient
suspected
COVID-19.
At
present,
reverse
transcription-polymerase
chain
reaction
(RT-PCR)
upper
respiratory
tract
samples
is
diagnostic
test
choice.
While
many
drugs
shown
vitro
activity
against
acute
syndrome
2
(SARS-CoV-2),
there
insufficient
data
promote
dissuade
their
usage.
Among
currently
available
drugs,
hydroxychloroquine
lopinavir/ritonavir
may
considered
patients
COVID-19
infection,
awaiting
further
trials.
Stringent
droplet
contact
precautions
will
protect
workers
exposures
Autoimmunity Reviews,
Journal Year:
2020,
Volume and Issue:
19(7), P. 102554 - 102554
Published: May 5, 2020
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
responsible
of
the
disease
2019
(COVID-19)
pandemic.
Therapeutic
options
including
antimalarials,
antivirals,
and
vaccines
are
under
study.
Meanwhile
current
pandemic
has
called
attention
over
old
therapeutic
tools
to
treat
infectious
diseases.
Convalescent
plasma
(CP)
constitutes
first
option
in
situation,
since
it
been
successfully
used
other
coronaviruses
outbreaks.
Herein,
we
discuss
possible
mechanisms
action
CP
their
repercussion
COVID-19
pathogenesis,
direct
neutralization
virus,
control
an
overactive
immune
system
(i.e.,
cytokine
storm,
Th1/Th17
ratio,
complement
activation)
immunomodulation
a
hypercoagulable
state.
All
these
benefits
expected
be
better
achieved
if
non-critically
hospitalized
patients,
hope
reducing
morbidity
mortality.
